Clinical Trial Update: DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial from MD Anderson uses DCE-MRI and molecular breast imaging to assess chemotherapy response in patients with triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING